Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 680

1.

The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages.

Huh JE, Jung IT, Choi J, Baek YH, Lee JD, Park DS, Choi DY.

Eur J Pharmacol. 2013 Jan 5;698(1-3):57-66. doi: 10.1016/j.ejphar.2012.08.013. Epub 2012 Sep 14.

PMID:
22985747
3.

Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.

Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH.

Mol Pharmacol. 2010 Jan;77(1):17-25. doi: 10.1124/mol.109.057877. Epub 2009 Oct 14.

4.

Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway.

Huh JE, Lee WI, Kang JW, Nam D, Choi DY, Park DS, Lee SH, Lee JD.

J Nat Prod. 2014 Nov 26;77(11):2423-31. doi: 10.1021/np500417d. Epub 2014 Nov 14.

PMID:
25397676
5.

12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.

Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, Xu J.

J Bone Miner Res. 2003 Dec;18(12):2159-68.

6.

Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.

Tsai HY, Lin HY, Fong YC, Wu JB, Chen YF, Tsuzuki M, Tang CH.

Eur J Pharmacol. 2008 Jun 24;588(1):124-33. doi: 10.1016/j.ejphar.2008.04.024. Epub 2008 Apr 16.

PMID:
18495114
7.

Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.

Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.

J Bone Miner Res. 2005 Apr;20(4):653-62. Epub 2004 Dec 6.

8.

The novel isoflavone derivatives inhibit RANKL-induced osteoclast formation.

Tang CH, Chang CS, Tan TW, Liu SC, Liu JF.

Eur J Pharmacol. 2010 Dec 1;648(1-3):59-66. doi: 10.1016/j.ejphar.2010.08.052. Epub 2010 Sep 17.

PMID:
20850430
9.

Water solution of onion crude powder inhibits RANKL-induced osteoclastogenesis through ERK, p38 and NF-kappaB pathways.

Tang CH, Huang TH, Chang CS, Fu WM, Yang RS.

Osteoporos Int. 2009 Jan;20(1):93-103. doi: 10.1007/s00198-008-0630-2. Epub 2008 May 28.

PMID:
18506384
10.

Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.

Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.

Biochem Pharmacol. 2013 Sep 15;86(6):782-90. doi: 10.1016/j.bcp.2013.07.015. Epub 2013 Aug 6.

PMID:
23928189
11.

Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.

Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.

J Bone Miner Res. 2011 Mar;26(3):644-56. doi: 10.1002/jbmr.242.

12.

Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.

Lee SY, Lee KS, Yi SH, Kook SH, Lee JC.

PLoS One. 2013 Dec 4;8(12):e80873. doi: 10.1371/journal.pone.0080873. eCollection 2013.

13.
14.

The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.

Yang J, Park OJ, Lee YJ, Jung HM, Woo KM, Choi Y.

Eur J Immunol. 2008 Jun;38(6):1598-609. doi: 10.1002/eji.200737650.

15.

Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.

Lee JW, Iwahashi A, Hasegawa S, Yonezawa T, Jeon WB, Cha BY, Nagai K, Woo JT.

J Nat Med. 2012 Jan;66(1):8-16. doi: 10.1007/s11418-011-0537-7. Epub 2011 Jun 9.

PMID:
21656335
16.

A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for experimental arthritis.

Cheng CP, Huang HS, Hsu YC, Sheu MJ, Chang DM.

J Clin Immunol. 2012 Aug;32(4):762-77. doi: 10.1007/s10875-012-9660-9. Epub 2012 Feb 23.

PMID:
22396044
17.

META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis.

Konda VR, Desai A, Darland G, Bland JS, Tripp ML.

Arthritis Rheum. 2010 Jun;62(6):1683-92. doi: 10.1002/art.27441.

18.

JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.

Ikeda F, Matsubara T, Tsurukai T, Hata K, Nishimura R, Yoneda T.

J Bone Miner Res. 2008 Jun;23(6):907-14. doi: 10.1359/jbmr.080211.

19.

Inhibition of inflammatory bone erosion by constitutively active STAT-6 through blockade of JNK and NF-kappaB activation.

Hirayama T, Dai S, Abbas S, Yamanaka Y, Abu-Amer Y.

Arthritis Rheum. 2005 Sep;52(9):2719-29.

20.

Supplemental Content

Support Center